Médicaments pour le traitement de la dépendance au cannabis Bibliothèque COCHRANE, 28 janvier 2019 Nielsen S, Gowing L, Sabioni P, Le Foll B https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD008940.pub3/full/fr#CD008940-abs-0002 Contexte L'usage de cannabis est relativement courant et répandu mondialement. Dans la plupart des régions du monde, les usagers de cannabis sont en demande croissante de traitements. La tendance à la dépénalisation ou à la légalisation de l'usage du cannabis dans certains pays va probablement faire perdurer cette tendance. Actuellement, il n'existe pas de traitements spécifiques pour la consommation de cannabis. Cette revue visait à évaluer l'efficacité et l'innocuité des médicaments pour le traitement de la dépendance au cannabis. Date de la [...]
Lire la suiteThe Endocannabinoid System and Cannabidiol’s Promise for the Treatment of Substance Use Disorder Yann Chye, Erynn Christensen, Nadia Solowij, and Murat Yücel Frontiers in Psychiatry, 19 February 2019, doi: 10.3389/fpsyt.2019.00063 Substance use disorder is characterized by repeated use of a substance, leading to clinically significant distress, making it a serious public health concern. The endocannabinoid system plays an important role in common neurobiological processes underlying substance use disorder, in particular by mediating the rewarding and motivational effects of substances and substance-related cues. In turn, a number of cannabinoid drugs (e.g., rimonabant, nabiximols) have been suggested for potential pharmacological treatment for substance dependence. Recently, cannabidiol [...]
Lire la suiteEndocannabinoid Signaling in Autism Bhismadev Chakrabarti, Antonio Persico, Natalia Battista, Mauro Maccarrone Neurotherapeutics, 2015, Volume 12, Issue 4, 837-847. DOI 10.1007/s13311-015-0371-9 Abstract Autism spectrum disorder (ASD) is a complex behavioral condition with onset during early childhood and a lifelong course in the vast majority of cases. To date, no behavioral, genetic, brain imaging, or electrophysiological test can specifically validate a clinical diagnosis of ASD. However, these medical procedures are often implemented in order to screen for syndromic forms of the disorder (i.e., autism comorbid with known medical conditions). In the last 25 years a good deal of information has been accumulated on the main components of [...]
Lire la suiteA cannabis reader : global issues and local experiences. Perspectives on cannabis controversies, treatment and regulation in Europe EMCDDA MONOGRAPHS, 8 Volume 1 Editors : Sharon Rödner Sznitman, Börje Olsson, Robin Room European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 2008 — 392 pp. Contents Introduction Foreword : Wolfgang Götz Overview of Volume 1 : Sharon Rödner Sznitman and Börje Olsson Part I : Cannabis in the past Chapter 1 : Cannabis as medicine in Europe in the 19th century : Manfred Fankhauser Chapter 2 : The re-emergence of the therapeutic use of cannabis products : recent developments and future prospects : John Witton Chapter 3 : The pharmacology of cannabis: [...]
Lire la suiteThe Treatment of Cannabis Use Disorder Itai Danovitch, David A. Gorelick, Chapter,The Assessment and Treatment of Addiction, january 2019 Abstract: Worldwide, cannabis is the most commonly used illicit substance. Approximately 8-12% of persons who use cannabis will develop cannabis use disorder (CUD) at some point in their life. Several psychosocial treatment methods have shown efficacy in controlled clinical trials, including motivational enhancement therapy, cognitive behavioral therapy, and contingency management. While no pharmacotherapy has been established as broadly effective for CUD, gabapentin and N-acetylcysteine have shown efficacy in single controlled clinical trials, and a number of promising approaches are under study. This article reviews established [...]
Lire la suiteCannabis Use Disorder During the Perinatal Period Martha L. Velez, Chloe J. Jordan, and Lauren M. Jansson Chapter 17, in : I. D. Montoya, S. R. B. Weiss (eds.), Cannabis Use Disorders, 2019, © Springer Nature Switzerland AG 2019 177 https://doi.org/10.1007/978-3-319-90365-1_17 Introduction Cannabis use in the perinatal period has been increasing in recent years, coincident with increasing legalization in the USA for medical or recreational purposes [1]. Marijuana is the most commonly used illicit drug during pregnancy [2], and among some populations, it is used more frequently than tobacco [3, 4]. Although the prevalence of cannabis use during pregnancy is difficult to ascertain with accuracy, [...]
Lire la suiteSynthetic Cannabinoids and Synthetic Cannabinoid-Induced Psychotic Disorders (Chapitre 9) Papanti Duccio*,†, Schifano Fabrizio†, Orsolini Laura†,‡ *Drug Addiction Centre, Latisana, Italy †University of Hertfordshire, Hatfield, United Kingdom ‡Polyedra Research Group, Teramo, Italy The Complex Connection Between Cannabis and Schizophrenia. (Chapitre 9) http://dx.doi.org/10.1016/B978-0-12-804791-0.00009-4 © 2018 Elsevier Inc. All rights reserved. INTRODUCTION Both phytocannabinoids, the psychoactive compounds naturally present in the cannabis plant, and synthetic cannabinoids (SCs; also known as synthetic cannabimimetics) exert their effects through alteration of the endocannabinoid system (Szabo, 2014). There are at least 104 different phytocannabinoids in cannabis, and their combination contributes to the psychoactive effects of cannabis (ElSohly & Gul, 2014). In 1967, the United States [...]
Lire la suiteDark Classics in chemical Neuroscience : Lysergic Acid Diethylamide (LSD), David E. Nichols, ACS Chemical Neuroscience, 2018, 9, 10, 2331-2334. doi: 10.1021/acschemneuro.8b00043. Abstract : LSD is one of the most potent psychoactive agents known, producing dramatic alterations of consciousness after submilligram (≥20 g) oral doses. Following the accidental discovery of its potent psychoactive effects in 1943, it was supplied by Sandoz Laboratories as an experimental drug that might be useful as an adjunct for psychotherapy, or to give psychiatrists insight into the mental processes in their patients. The finding of serotonin in the mammalian brain in 1953, and its structural resemblance to LSD, quickly led [...]
Lire la suiteClinical and Preclinical Evidence for Functional Interactions of Cannabidiol and Δ9-Tetrahydrocannabinol Douglas L. Boggs, Jacques D. Nguyen, Daralyn Morgenson, Michael A. Taffe and Mohini Ranganathan Neuropsychopharmacology. 2018 Jan; 43(1): 142–154. Published online 2017 Oct 18. Prepublished online 2017 Sep 6. doi: 10.1038/npp.2017.209 PMCID: PMC5719112 PMID: 28875990 Abstract The plant Cannabis sativa, commonly called cannabis or marijuana, has been used for its psychotropic and mind-altering side effects for millennia. There has been growing attention in recent years on its potential therapeutic efficacy as municipalities and legislative bodies in the United States, Canada, and other countries grapple with enacting policy to facilitate the use of cannabis or its constituents for [...]
Lire la suiteCannabidiol provides viable treatment opportunity for multipleneurological pathologies of autism spectrum disorder Bin Gu Global Drugs and Therapeutics, Review article, 2017, 2, 6, 1-4 doi: 10.15761/GDT.1000134 Abstract Autism spectrum disorder (ASD)is a heterogeneous neurodevelopmental disorderaffecting over 1% of the general population. While it is well established that ASD stems from a combination of genetic and environmental factors, there are no defined mechanisms of pathogenesis, rendering curative therapy very difficult to establish. No effective therapy exists for ASD, presenting an urgent clinical need for better control of common core pathologies of ASD regardless of its etiology. Cannabidiol (CBD), a major phytocannabinoid constituent of the cannabis plant, is [...]
Lire la suite